百靈雲生醫科技股份有限公司
Update：2026/09/15
Industries
Main Industry
Health Care
Main Product/Service
The primary business operations of 百靈雲生醫科技股份有限公司 include the research and development of innovative medical imaging technologies, the research and development of novel SPECT tumor diagnostic drugs, the development of clinical service products, and the promotion of clinical application products. The nuclear medicine SPECT cardiovascular auxiliary diagnostic system independently developed by the team of 百靈雲生醫科技股份有限公司 will establish a new standard in cardiovascular diagnosis and prevention. Clinically, it will address the issue in Asian regions such as Taiwan and Mainland China where a shortage of PET cardiac imaging agents prevents the delivery of cardiovascular medical services on par with Europe and the United States. Meanwhile, the auxiliary diagnostic service products for oncology and Parkinson's disease will enhance medical service quality and reduce the expenditure and waste of medical resources, thereby elevating the international influence and standing of Taiwan's healthcare from the perspective of health economics.
(The content above was translated by AI.)
(The content above was translated by AI.)
Founded Year
2014
Unified Business No.
24547450
Status
Active
Number of Employees
7
Total Paid-in
Capital
10,000,000 (NT$)
Location of Company
Taiwan
, New Taipei City
Information such as company name, company status, responsible person, year of establishment, paid-in capital, and registered address is sourced from the Commercial and Industrial Registration Office of the Ministry of Economic Affairs; listing status includes emerging stock, M&A, and IPO; overseas development is provided by the startup itself.
Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
The founder of Bailing Cloud Biomedical Technology Co., Ltd. is Dr. Bailing Xu, a US-trained cardiovascular imaging expert with many years of rich experience in American academia and industry. Currently, the company's management team consists of 3 PhDs, 3 Master's degree holders, and 1 Bachelor's degree holder, all of whom possess specialized expertise in their respective related fields. The company's primary business operations include the research and development of innovative medical imaging technologies, the research and development of novel SPECT tumor diagnostic drugs, the development of clinical service products, and the promotion of clinical application products. Taking the benefit of more patients as its starting point, the company's core value is to guide clinical service products through innovative technology and widely promote clinical applications, thereby creating medical economic output value. Therefore, the company's development path combines the characteristics of clinical academic research, clinical medicine, and the biomedical technology industry. Through the effective integration of resources from all aspects, it truly realizes the economic value of innovative technologies from practical clinical applications, while simultaneously pioneering an emerging development model for the biomedical industry.
(The content above was translated by AI.)
(The content above was translated by AI.)
